News Features Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate Michael O'Riordan November 27, 2017
News Daily News Radial Access Best for PCI Following Thrombolysis in STEMI Michael O'Riordan November 27, 2017
News Conference News AHA 2017 Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List Michael O'Riordan November 12, 2017
News Daily News Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients Michael O'Riordan October 26, 2017
News Daily News Statins and Diabetes: Causal Link Reinforced in New Analysis Michael O'Riordan October 25, 2017
News Daily News Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests Michael O'Riordan October 20, 2017
News Daily News New Performance and Quality Metrics for STEMI and NSTEMI Care Michael O'Riordan September 21, 2017
News Daily News Study Questions Incremental Benefit of Beta-Blockers After Acute MI Michael O'Riordan September 21, 2017
News Daily News Ischemic Heart Disease the Leading Cause of Death Globally Michael O'Riordan September 19, 2017
News Conference News ESC 2017 Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1 Michael O'Riordan September 05, 2017
News Conference News ESC 2017 Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets Michael O'Riordan August 30, 2017
News Conference News ESC 2017 Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed Michael O'Riordan August 29, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2017 ESC Updates Guidelines for Treating STEMI Patients Michael O'Riordan August 27, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Daily News Evolocumab Not Cost-Effective at Current List Price Michael O'Riordan August 23, 2017
News Daily News Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests Michael O'Riordan August 14, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017
News Daily News CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition Michael O'Riordan August 04, 2017
News Daily News ‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low Michael O'Riordan August 01, 2017